Fintel reports that on September 4, 2026, Citigroup initiated coverage of Dianthus Therapeutics (NASDAQCM:DNTH) with a Buy recommendation.
Dianthus Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing primarily on developing innovative therapeutic solutions. The company is dedicated to advancing the field of immunology, with a significant emphasis on designing and commercializing novel treatments meant to address autoimmune and inflammatory diseases. Key projects include the development of targeted therapies that aim to modulate the immune system in a precise manner, thereby offering potential benefits over traditional treatments with fewer side effects and improved efficacy. Dianthus Therapeutics leverages cutting-edge research and technology to build a robust pipeline of drug candidates, positioning it as a formidable player in the medical research arena focused on transformative healthcare solutions.
Prior to this rating action, the stock closed at $107.85 on September 3, 2026. The latest close on September 4, 2026, was $108.10. This represents a one-week price change of +2.14% from the baseline close of $105.84 on August 28, 2026. Over a longer period, the stock experienced a one-month price change of -2.08% from the baseline close of $110.40 on August 4, 2026.
In terms of broader analyst sentiment, the current consensus target mean as of August 28, 2026, was $142.14, with a median target of $135.15. This current mean represents a consensus target revision of +9.14% from the prior consensus target mean of $130.25 recorded on August 4, 2026. The current consensus target mean implies a change of +31.49%.
For the current recommendation period of September 1, 2026, the aggregate analyst recommendations show 10 strong buy, 11 buy, 1 hold, 0 sell, and 0 strong sell ratings. This total of 22 recommendations translates to 95.5% positive, 4.5% hold, and 0.0% negative recommendations. This distribution remains unchanged from the prior recommendation period of August 1, 2026, which also recorded 10 strong buy, 11 buy, 1 hold, 0 sell, and 0 strong sell ratings.
Other recent analyst actions include Truist Securities maintaining its Buy rating on August 6, 2026, and HC Wainwright & Co. also maintaining its Buy rating on the same day. On August 5, 2026, Wedbush maintained its Outperform rating.
Dianthus Therapeutics reported its latest earnings on August 4, 2026. The company reported an actual EPS of -0.9, compared to the estimated EPS of -0.8748. Actual revenue was $761,000,000,000.00, compared to the estimated revenue of $263,751,000,000.00.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 4, 2026 | Citigroup | Buy | initiated coverage | |
| August 6, 2026 | Truist Securities | Buy | Buy | maintained |
| August 6, 2026 | HC Wainwright & Co. | Buy | Buy | maintained |
| August 5, 2026 | Wedbush | Outperform | Outperform | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
